Drug use surveillance of Takecab for Supplement to Helicobacter pylori eradicatio
Not Applicable
- Conditions
- The following diseases in patients for whom H. pylori will be eradicated with triple therapy: Gastric ulcer, duodenal ulcer, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, idiopathic thrombocytopenic purpura, stomach following endoscopic treatment of early gastric cancer, or H. pylori gastritis
- Registration Number
- JPRN-jRCT1080222951
- Lead Sponsor
- TAKEDA PHARMACEUTICAL COMPANY LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Participants who meet the following criteria will be included.
1.Participants receiving H. pylori eradication treatment for the first time
2.Participants for whom H. pylori eradication with Takecab tablets or proton pump inhibitor + amoxicillin + clarithromycin was found unsuccessful and who will receive eradication treatment with amoxicillin and metronidazole
Exclusion Criteria
Participants who meet any of the following criteria will not be included. Refer to the Contraindications and Precautions section of the package insert of antimicrobials used in triple therapy.
1.Participants with previous history of hypersensitivity to ingredients in Takecab tablets
2.Participants taking atazanavir sulfate or rilpivirine hydrochloride
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method